| 项目编号 |
PRJCA013169 |
| 项目标题 |
Proteogenomics of Clear Cell Renal Cell Carcinoma Response to Tyrosine Kinase Inhibitor |
| 涉及领域 |
Medical |
| 数据类型 |
Transcriptome or Gene expression
|
| 物种名称 |
Homo sapiens
|
| 描述信息 |
Integrated proteogenomic characterization of 115 tumors from patients with clear cell renal cell carcinoma (ccRCC) undergoing Sunitinib treatment in Chinese population revealed the molecular basis of differential clinical outcomes with tyrosine kinase inhibitor (TKI) therapy. We found that chromosome 7q gain-induced mTOR signaling activation was associated with poor therapeutic outcomes with Sunitinib treatment, whereas the aristolochic acid signature and VHL mutation synergistically caused enhanced glycolysis was correlated with better prognosis. The proteomic and phosphoproteomic analysis further highlighted the responsibility of mTOR signaling for non-response to Sunitinib. Immune landscape characterization revealed diverse tumor microenvironment subsets in ccRCC, among which the progenitor-infiltrated group manifested upregulated platelet aggregation and poor prognosis to therapy. To better direct the selection of treatment, we constructed a proteomic classifier and verified its robustness in an independent dataset. Overall, our proteogenomic analyses revealed associations between ccRCC molecular characteristics and the response to TKI, which can facilitate future improvement of therapeutic responses. |
| 样品范围 |
Monoisolate |
| 发布日期 |
2023-06-13 |
| 出版信息 |
| PubMed ID |
文章标题 |
杂志名称 |
Doi |
发表年份 |
| 37460463
|
Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor
|
Nature Communications
|
10.1038/s41467-023-39981-6
|
2023
|
|
|
| 项目资金来源 |
| 机构 |
项目类型 |
授权项目ID |
授权项目名称 |
| National Natural Science Foundation of China (NSFC)
|
Key Program
|
2019YFA0801900
|
|
|
|
| 提交者 |
Chen
Ding (chend@fudan.edu.cn)
|
| 提交单位 |
Fudan University |
| 提交日期 |
2022-11-12 |
